NCT04729153

Brief Summary

Evaluate effect of DAADs on covid-19 disease.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 23, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 28, 2021

Completed
4 days until next milestone

Study Start

First participant enrolled

February 1, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2022

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

February 3, 2021

Status Verified

January 1, 2021

Enrollment Period

1 year

First QC Date

January 23, 2021

Last Update Submit

January 30, 2021

Conditions

Covid19

Outcome Measures

Primary Outcomes (1)

  • Evaluate the effect of DAADs on covid -19

    If chronic HCV patients who received DAADs suspected to be infected by covid-19 by having findings suggest covid 19 infection in MSCT chest or clinically symptoms or confirmed by nasopharyngeal swab . And if infected what about severity , if they need hospital admission or oxygen therapy or mechanical ventilation ,if they still alive or died

    12 months (from 1/2/2021 to 1/2/2022)

Study Arms (2)

Chronic HCV patients previously treated by DAADs.

Drug: DAAD Compound

Chronic HCV patients not treated by DAADs yet.

Interventions

DAAD CompoundDRUG

Sofosbuvir , Daclatasvir and ribavirin

Chronic HCV patients previously treated by DAADs.

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Retrospective study

You may qualify if:

  • HCV patient with or without LC.
  • \>18 years old.
  • Received DAADs at 2019.

You may not qualify if:

  • Combined HCV and HIV infected patients.
  • Combined HCV and HBV infected patients.
  • \< 18 years old.
  • Pregnant or breast-feeding patients.
  • Patients with autoimmune disease.
  • Patients with multiorgan failure, active cancer, renal insufficiency.
  • Patients received immunosuppressive drugs.
  • Immune compromised patients.
  • Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

COVID-19

Interventions

1,4-diacrylateanthracene-9,10-dione

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Eman Adel

CONTACT

01096883754emanadel9594@gmail.com

Nahed Ahmed

CONTACT

0 100 361 1626nahedmak@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

January 23, 2021

First Posted

January 28, 2021

Study Start

February 1, 2021

Primary Completion

February 1, 2022

Study Completion

March 1, 2022

Last Updated

February 3, 2021

Record last verified: 2021-01